Published in J Clin Oncol on November 10, 2007
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol (2015) 2.09
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst (2014) 2.01
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model. Curr Opin Support Palliat Care (2010) 1.08
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys (2010) 1.07
Electronic toxicity monitoring and patient-reported outcomes. Cancer J (2011) 1.06
Patient engagement as an emerging challenge for healthcare services: mapping the literature. Nurs Res Pract (2012) 1.05
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol (2009) 1.00
Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.98
Improving patient safety via automated laboratory-based adverse event grading. J Am Med Inform Assoc (2011) 0.96
Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol (2016) 0.94
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer (2012) 0.92
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer (2016) 0.92
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer (2010) 0.90
Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. Gastrointest Cancer Res (2012) 0.89
Incidence of adverse events in an integrated US healthcare system: a retrospective observational study of 82,784 surgical hospitalizations. Patient Saf Surg (2014) 0.89
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol (2013) 0.89
Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers' use of the information: a randomized controlled clinical trial. Support Care Cancer (2014) 0.89
Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis (2008) 0.86
Concordance between patient reports of cancer-related symptoms and medical records documentation. J Pain Symptom Manage (2012) 0.85
[The benefits of using patient-reported outcomes in cancer treatment: an overview]. Wien Klin Wochenschr (2012) 0.85
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol (2015) 0.83
Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data. J Oncol Pract (2014) 0.83
Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients. Strahlenther Onkol (2012) 0.82
Using patient-reported outcome measures for improved decision-making in patients with gastrointestinal cancer - the last clinical frontier in surgical oncology? Front Oncol (2013) 0.80
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer (2011) 0.80
High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One (2015) 0.77
Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing. Support Care Cancer (2016) 0.77
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol (2017) 0.76
Outcomes research: Integrating PROs into the clinic - overall survival benefit or not, it's worth the trouble. Nat Rev Clin Oncol (2017) 0.76
Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival. J Geriatr Oncol (2013) 0.76
Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Trials (2009) 0.76
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol (2016) 0.75
News from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity. Transl Behav Med (2016) 0.75
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Am Health Drug Benefits (2016) 0.75
Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol (2017) 0.75
Review of a study of duloxetine for painful chemotherapy-induced peripheral neuropathy. J Adv Pract Oncol (2013) 0.75
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. Cancer (2014) 0.75
The use of and adherence to CTCAE v3.0 in cancer clinical trial publications. Oncotarget (2016) 0.75
Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data. JMIR Med Inform (2016) 0.75
Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument. Clin Ther (2016) 0.75
Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer (2016) 0.75
Palliative oncology: identity, progress, and the path ahead. Ann Oncol (2012) 0.75
Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Front Pharmacol (2016) 0.75
Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. BMC Cancer (2017) 0.75
Chemotherapy interruptions in relation to symptom severity in advanced breast cancer. Support Care Cancer (2015) 0.75
Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open (2017) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Against diagnosis. Ann Intern Med (2008) 3.69
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol (2006) 2.53
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol (2003) 2.38
Therapeutic applications of fenugreek. Altern Med Rev (2003) 2.12
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin (2012) 1.94
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care (2012) 1.84
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Head and neck cancers. J Natl Compr Canc Netw (2011) 1.64
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol (2011) 1.50
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Ann Surg Oncol (2014) 1.45
Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol (2011) 1.41
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med (2010) 1.40
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2014) 1.39
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol (2005) 1.39
Targeted drugs for metastatic renal cell carcinoma. Lancet (2007) 1.36
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.35
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol (2013) 1.34
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol (2005) 1.33
Patients' responsibility to participate in decision making and research. JAMA (2013) 1.32
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res (2004) 1.25
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res (2005) 1.23
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst (2011) 1.21
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res (2013) 1.21
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer (2013) 1.21
Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol (2012) 1.20
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2012) 1.18
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs (2004) 1.17
Biased view of the role of site-specific therapy in carcinoma of unknown primary. J Clin Oncol (2013) 1.16
Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health (2012) 1.15
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance. Drug Saf (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics (2003) 1.10
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer (2006) 1.08
Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother (2004) 1.07
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs (2007) 1.04
Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study. Cancer (2011) 1.02
Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head Neck (2011) 1.00
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak (2010) 0.98
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage (2010) 0.94
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck (2014) 0.93
The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. Qual Life Res (2011) 0.92
Evidence-based systematic review of dandelion (Taraxacum officinale) by natural standard research collaboration. J Herb Pharmacother (2005) 0.91
Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer (2012) 0.91
Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med (2005) 0.90
Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 0.90
Mucosal melanoma of the head and neck. J Natl Compr Canc Netw (2012) 0.89
Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys (2012) 0.89
Fenugreek (Trigonella foenum-graecum L. Leguminosae): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother (2007) 0.88
Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. J Soc Integr Oncol (2006) 0.88
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther (2007) 0.88
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage (2011) 0.88
Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 0.87
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol (2012) 0.86
Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys (2011) 0.86
Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf (2005) 0.85
Commentary: encouraging clinicians to incorporate longitudinal patient-reported symptoms in routine clinical practice. J Oncol Pract (2011) 0.85
Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines? J Oncol Pract (2011) 0.85
Horse chestnut:a multidisciplinary clinical review. J Herb Pharmacother (2002) 0.85
Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. Pain (2011) 0.84
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol (2012) 0.84
Controversies in the locoregional management of head and neck cancer. J Natl Compr Canc Netw (2011) 0.84
An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration. Expert Opin Drug Saf (2006) 0.84
An evidence-based systematic review of Aloe vera by the natural standard research collaboration. J Herb Pharmacother (2007) 0.84
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol (2008) 0.83
Andrographis paniculata for the treatment of upper respiratory infection: a systematic review by the natural standard research collaboration. Explore (NY) (2006) 0.82
Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. J Oncol Pract (2012) 0.82
Peppermint (Mentha piperita): an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother (2007) 0.82
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst (2014) 0.82
An evidence-based systematic review of bilberry (Vaccinium myrtillus) by the Natural Standard Research Collaboration. J Diet Suppl (2009) 0.81
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res (2005) 0.81
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs (2007) 0.81
Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research. Value Health (2011) 0.81
A review of quality of care evaluation for the palliation of dyspnea. Am J Respir Crit Care Med (2010) 0.80
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer (2002) 0.80
An evidence-based systematic review of belladonna by the natural standard research collaboration. J Herb Pharmacother (2004) 0.80
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. Pain Med (2012) 0.80
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol (2010) 0.80
Devil's Claw (Harpagophytum procumbens DC): an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother (2006) 0.79